Difference between revisions of "Pancreatic cancer - historical"
Jump to navigation
Jump to search
(Created page with "The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s)...") |
|||
| Line 8: | Line 8: | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | |||
| + | =Metastatic disease, first-line= | ||
| + | ==PEFG {{#subobject:f0e123|Regimen=1}}== | ||
| + | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
| + | |- | ||
| + | |[[#top|back to top]] | ||
| + | |} | ||
| + | PEFG: '''<u>P</u>'''latinol (Cisplatin), '''<u>E</u>'''pirubicin, '''<u>F</u>'''luorouracil, '''<u>G</u>'''emcitabine | ||
| + | ===Regimen {{#subobject:5d6ee0|Variant=1}}=== | ||
| + | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
| + | !style="width: 20%"|Study | ||
| + | !style="width: 20%"|Years of enrollment | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
| + | !style="width: 20%"|Comparator | ||
| + | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
| + | |- | ||
| + | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70175-3/abstract Reni et al. 2005] | ||
| + | |2000-2003 | ||
| + | | style="background-color:#1a9851" |Phase III (E-esc) | ||
| + | |[[Pancreatic_cancer#Gemcitabine_monotherapy_3|Gemcitabine]] | ||
| + | | style="background-color:#91cf60" |Seems to have superior PFS | ||
| + | |- | ||
| + | |} | ||
| + | ====Chemotherapy==== | ||
| + | |||
| + | *[[Cisplatin (Platinol)]] 40 mg/m<sup>2</sup> IV once on day 1 | ||
| + | *[[Epirubicin (Ellence)]] 40 mg/m<sup>2</sup> IV once on day 1 | ||
| + | *[[Fluorouracil (5-FU)]] 200 mg/m<sup>2</sup>/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m<sup>2</sup>) | ||
| + | *[[Gemcitabine (Gemzar)]] 600 mg/m<sup>2</sup> IV over 60 minutes once per day on days 1 & 8 | ||
| + | |||
| + | '''28-day cycles''' | ||
| + | |||
| + | ===References=== | ||
| + | |||
| + | #Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(05)70175-3/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15925814 PubMed] | ||
=Metastatic disease, all lines of therapy= | =Metastatic disease, all lines of therapy= | ||
Revision as of 13:45, 15 May 2021
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.
3 regimens on this page
3 variants on this page
|
Metastatic disease, first-line
PEFG
| back to top |
PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Reni et al. 2005 | 2000-2003 | Phase III (E-esc) | Gemcitabine | Seems to have superior PFS |
Chemotherapy
- Cisplatin (Platinol) 40 mg/m2 IV once on day 1
- Epirubicin (Ellence) 40 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m2)
- Gemcitabine (Gemzar) 600 mg/m2 IV over 60 minutes once per day on days 1 & 8
28-day cycles
References
- Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article contains protocol PubMed
Metastatic disease, all lines of therapy
SMF
| back to top |
SMF: Streptozotocin, Mitomycin, 5-Fluorouracil
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Kelsen et al. 1991 | 1987-1989 | Phase III (C) | CAC | Superior OS |
Chemotherapy
References
- Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. link to original article PubMed